AstraZeneca wins speedy FDA review for Imfinzi to challenge Roche in small cell lung cancer

2nd December 2019 Uncategorised 0

The FDA has put AstraZeneca’s Imfinzi in the fast lane toward a potential nod in previously untreated small cell lung cancer, where Roche’s Tecentriq has been the sole player since March. While the two performed similarly in trials in terms of patient survival, Imfinzi offers physicians an additional liberty.

More: AstraZeneca wins speedy FDA review for Imfinzi to challenge Roche in small cell lung cancer
Source: fierce